Consumer biotechnology hardware and home food cultivation devices
Strategic Profile
Hypha Labs has developed the first in-home mushroom accelerator to allow production of high-quality mushroom ingredients in an eight-day cycle. The company is currently conducting a Regulation A+ public offering to support expansion from consumer devices to large-scale ingredient production.
Cyborg Score Rationale
The company reports zero revenue in the trailing period, indicating lack of recurring sales or commercial traction, and without material product commercialization cannot organically fund operations. Market cap stands at $5.9 million with limited analyst coverage.
Top Insights
The company announced expansion of Mushroom Accelerator technology to support production of three functional mushroom varieties—Reishi, Lion's Mane, and Cordyceps—in an eight-day home cultivation cycle.
With a $5.9 million market cap and 155.52 million shares outstanding, the company trades on OTC Pink with extremely low valuation per share.
Lean operating structure with small headcount implies low fixed overhead and operational flexibility, reducing cash required for operations and preserving runway.
Recent Developments
(August 2024) Name and ticker change from Digipath (DIGP) to Hypha Labs (FUNI)
(August 2025) Expanded MicroPearls Accelerator technology supporting Reishi, Lion's Mane, and Cordyceps production
(June 2025) Company pursuing Regulation A+ public offering for expansion to commercial-scale production
Open the full interactive Hypha Labs, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.